Interim report April - September 2019
CEO’s commentsFinanciallyThe investments EQL Pharma made in its product portfolio in recent years continue to provide good returns. For the second quarter in a row, sales increased by more than 30 percent compared to the same period last year. Quarterly sales are also the company's best since the company was founded. Through efficient working capital financing, cash liquidity is good despite large continued investments in the product portfolio. MarketDuring the quarter, EQL Pharma got its first hospital product approved. The product is approved for sale in Sweden, Denmark, Norway and